Scientific Advisory Board

DR THERESA LAVALLEE Vice President, Translational Medicine DR STEVEN TOWNSON, Parker Institute for Cancer Senior Principal Scientist, Early Oncology Immunotherapy Development, Merck Research Laboratories DR BIOL. SCI. ALESSANDRO SETTE Center Head, Division Head, and PROF BALI PULENDRAN, Professor Center for Infectious Disease, Professor in the Department of Pathology La Jolla Institute and Laboratory Medicine, Stanford DR PETER HOTEZ, University School of Medicine Dean of National School of Tropical Medicine, Director, Texas Children’s Hospital Center Baylor College of DR MARIA KARASARIDES, Medicine Executive Director, ImmunoOncology, Regeneron Pharmaceuticals DR JERALD SADOFF, Senior Advisor, Janssen Infectious Diseases and Vaccines DR EZRA COHEN, Professor of Medicine, UC San Diego Moores DR ROY BAYNES, Cancer Center, Co-Director, San Diego Center Senior Vice President Global Clinical for Precision Immunotherapy Development and Chief Medical Officer, Merck Research Laboratories DR. WAYNE C. KOFF, DR KARIN JOOSS, President and CEO, The Human Executive Vice President of Research, Vaccines Project and Chief Scientific Officer, Gritstone Oncology Confirmed Speakers

• Dr Evanthia Galanis, Chair Molecular Medicine, Professor of Oncology, Mayo Clinic • Dr Ignacio Wistuba, Professor & Chair, Department of Translational Molecular Pathology, MD Anderson Cancer Center • Dr Ezra Cohen, Professor of Medicine, UCSD Moores Cancer Center, Co-director, San Diego Center for Precision Immunotherapy • Dr Sean Tucker, CSO and Vice President Research, Vaxart • Dr. Steven Townson, Senior Principal Scientist, Early Oncology Development, Merck Research Laboratories • Dr Peter Hotez, President of the Sabin Vaccine Institute & Dean of National School of Tropical Medicine, Baylor College of Medicine • Dr Rachel Clemens, Commercial Innovation Manager, Center for the Advancement of Science in Space • Dr Susan Old, Acting Deputy Director, NIAID • Dr Vu Truong, Chief Executive Officer and Chief Scientific Officer, Aridis Pharmaceuticals • Dr Maria Karasarides, Executive Director, Immuno-Oncology, Regeneron Pharmaceuticals • Rajeev Dadoo, Partner, SR One • Mary Jo Potter, CEO and Managing Director, Healthcare Angels • Dr Kathrin Janssen, SVP, Head of Vaccine Research & Development, Pfizer • Dr Alexander Kort, Senior Vice President Corporate Development, Themis Bioscience GmbH Themis • Dr Biol. Sci. Alex Sette Center Head, Division Head, and Professor, Center for Infectious Disease, La Jolla Institute for Immunology • Dr Kirsteen Maclean, PhD., Associate, Scientific Director, Biomarker & Translational Strategy Definiens • Dr Robert Hollingsworth, Vice President & CSO Cancer Vaccines, Pfizer • Dr Steven Reed, Founder, Distinguished Scientist, IDRI • Dr Pravin Kaumaya, Professor, Director, Div. Vaccine Res & Peptide/Protein Engineering laboratory, The Ohio State University College of Medicine • Michael Murray, Analyst, Biotechnology Value Fund • Dr Gary Starling, Associate Vice President, Protein Science, Merck • Dr Hanspeter Gerber, CSO, 3T Biosciences • Dr Stephen Schoenberger, Center Head; Professor, Division of Developmental Immunology, LaJolla Institute for Immunology • Dr Raymond Tesi, Co-Founder, President & CEO, INmune Bio • Dr Roland Dunbrack, Director, Molecular Modeling Facility, Fox Chase Cancer Center • Dr Vadim Klyushnichenko, Vice President of Pharmaceutical Development & Quality, Calibr – A division of Scripps Research • Dr Mike Schopperle, CEO, CureMeta LLC. • Dr Martin Moore, Co-Founder & CEO, Meissa Vaccines • Chester Kitchen, Cancer Patient Advocate • Dr Jeffrey Froude, Major, Stm, Vaccines/Therapeutics Division, Defense Threat Reduction Agency • Dr Lesley Stolz, EVP & Chief Business Officer, Annexon Biosciences • Dr Raphael Rousseau, EVP, Head of Product Development, CMO, Gritstone Oncology • Dr Andrew Lees, Scientific Director, Fina Biosolutions • Javad M. Aman, President and CSO, Integrated Biotherapeutics • Dr Sangeeta Tiwari, Associate (faculty), Albert Einstein College of Medicine Confirmed Speakers

• Dr Louis-Philippe Vézina, PhD, CEO, Angany Inc. • Dr Nancy Sullivan, Chief and Biodefense Research Section, Vaccine Research Center National Institutes of Health • Jan Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen • Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen Infectious Diseases and Vaccines • Dr Kalpit Vora, Director, infectious disease and Vaccine Basic Research, Merck • Dr Chia-Wei Tsai, Branch Chief, Antiviral and Antitoxin programs, BARDA • Dr. Sina Bavari, Science Director, US Army Medical Research Institute of Infectious Diseases, USAMRIID • Dr Richard Scheuermann, Director, La Jolla Campus, J. Craig Venter Institute • Dr Nabil Al Humadi, Pharmacologist and Toxicologist, Food and Drug Administration • Dr Clemencia Pinilla, Associate Member, Torrey Pines Institute for Molecular Studies • Dr Duncan Mwangi, Research Director, Zoetis • Dr Darrick Carter, Vice President - Adjuvant Technology, IDRI • Dr Leonard Friedland, Vice President, Scientific Affairs and Public Health Vaccines, North America, GSK • Dr Jun Tang, Senior Manager, CRI Venture Fund and Clinical Accelerator, Cancer Research Institute • Dr Larry Zeitlin, President, Mapp Biopharmaceutical, Inc • Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, Merck • Dr Steven Kleiboeker, Vice President, Research & Development, Viracor Eurofins BioPharma Services • Dr Tom Davis, CMO, Genocea • Professor Bali Pulendran, Professor in the Department of Pathology and Laboratory Medicine, Stanford University School of Medicine • Dr Beckie Ingram, Principal Investigator, Queens University Belfast • Dr Bruce Keyt, CSO, IGM Biosciences • Dr Alexander Koglin, PhD, Co-founder, Chief Science and Technology Officer, NTxBIO • Dr Ofer Levy, Director, Precision Vaccines Program, Boston Children’s Hospital & Professor, Harvard Medical School • Dr Hasan Jafri, Senior Director, Clinical Research and Development, Infectious Disease and Vaccines, MedImmune • Dr Praveen Bommareddy, Translational Research Lead, Replimmune • Dr Wouter Hazenbos, Scientist, Genentech • Dr Kevin Killeen, Chief Scientific Officer, Matrivax • Dr Naik Rumi Armaghan, Ph.D., Director and Head of Design Sciences in FluNXT, Sanofi Pasteur’s “Biotech-lite” • Dr Sean Bennett, Senior Director, Clinical Development and Medical Affairs, Emergent BioSolutions • Sarah Royalty Tredo, Senior Director, Emergent Biosolutions • Dr Helen Sabzevari, President, Precigen • Charles Heffernan, Member, BioPhorum Operations Group; Director, CRB • Dr Justin Moran, Senior Director Bioprocess Development, Pfizer • Dr Lakshmi Khandke, Senior Program Advisor, Center for Vaccine Innovation & Access, PATH • Dr Karen Aboody, Professor, Department of Developmental & Stem Cell Biology and Division of Neurosurgery, City of Hope; Founder & CSO, TheraBiologics • Dr Michael J. Mitchell, Ph.D., Skirkanich Assistant Professor of Innovation, Department of Bioengineering, University of Pennsylvania • Dr Aubree Gordon, Associate Professor of Epidemiology, University of Michigan Confirmed Speakers

• Dr Jason Comer, Assistant Professor, Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston • Dr John Ross, Vice President, Protein Therapeutics, Cue Biopharma • Dr Chris Clegg, President, Founder & CSO, TRIA Bioscience • Dr William Smith, Chief Executive Officer, Alliance for Multispecialty Research LLC • Dr Timothy Cooke, CEO and Board member, NovaDigm Therapeutics • Dr I-Ming Wang, Director, Translational Oncology, Pfizer • Dr Mary Redman, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center • Dr David Canton, Director, R&D and Clinical Science, OncoSec • Dr Jon Wigginton, SVP, Clinical Development & Chief Medical Officer, MacroGenics • Dr Bruno Anspach, Director of Clinical Operations Latin America - vaccines, GSK • Dr Joseph Kim, Chief Executive Officer, Inovio Pharmaceuticals • Dr Brian Price, COO, Blue Water Vaccines, Inc • Dr Craig Thomson, CSO, Blue Water Vaccines, Inc • Dr Willem Hanekom, Deputy Director, TB Vaccines, Bill & Melinda Gates Foundation • Dr Eric Appel, Assistant Professor of Material Science and Engineering, Stanford University • Dr Ali Harandi, Lab head, Dpt of Microbiology & Immunology, University of Gothenburg • Dr Timothy W Phares, Head of Immunology, Explorations in Global Health (ExGloH), Leidos • Dr Maureen Bruhns, Senior Director of Analytical Development, Sutro Bio • Dr Jo Anne Welsch, Scientific Director, Group B Streptococcal Vaccine Project, PATH • Dr Ovid Trifan, CMO & SVP Clinical Development, Apexigen • Dr William Heath, Professor, University of Melbourne, Scientific Advisor, Avalia Immunotherapies Limited • Dr Mark Davis, Professor, Microbiology & Immunology, Director, Stanford Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine • Dr Kyle Smith, PhD, Director, Research and Development, Micromedicine • Dr Tony Reid, CSO, EpicentRx • Dr Andreas Niethammer, Senior Vice President, Head of Clinical Development Immunotherapy for Solid Tumors, Sorrento Therapeutics • Dr Theresa LaVallee, Vice President, Translational Medicine, Parker Institute for Cancer Immunotherapy • Dr Martina Sersch, CMO, Mustang Bio • Dr Angelos Stergiou, CEO, SELLAS • Dr Stephen Nagler, Executive Director, MedPro Investors • Dr Vanessa Jonsson, Assistant Research Professor, City of Hope • Seth Bannon, Founding Partner, Fifty Years • Dr Jennifer Cochran, Chief Scientist, Lagunita Biosciences • Dr Wouter Meuleman, Director, Venture Investments, Illumina Ventures • Dr Farshad Guirakhoo, CSO, GeoVax • Dr Bita Sahaf, Senior Research Scientist; Center for Cancer Cell Therapy, Stanford Cancer Institute; Technical Director, Stanford Cancer Correlative Science Unit (CCSU); Correlatives for Parker Institute for Immunotherapy; Scientific Director, Stanford CIMAC • Dr Adil Daud, Clinical Professor of Medicine, Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center • Dr Pralay Mukhopadhyay, Head of Late stage IO, Oncology Biometrics, AstraZeneca • Dr David Whitacre, Senior Vice President, VLP Biotech Confirmed Speakers

• Dr Lacey Kitch, Director, Informatics at Parker Institute for Cancer Immunotherapy • Dr Nancy Whiting, Senior Vice President, Development, Seattle Genetics • Dr Xiaoping Zhu, Interim Associate Dean & Department Chair, University of Maryland • Dr Grace Chen, Deputy Chief of The Clinical Trials Program in the VRC, NIH • Dr Sari Pesonen, Vice President Scientific And Clinical Development, Co-Founder, Valo Therapeutics • Dr Francesca Milletti, Associate Director Translational Medicine, Kite, a Gilead Company • Dr Trevor Clancy, Chief Scientific Officer, NEC OncoImmunity AS • Dr Mike Stebbins, MCDC Executive Director, Medical CBRN Defense Consortium (MCDC) • Dr James Wassil, Vice President and GH&V BU Head, Vaccines, Pfizer • Dr Juan Salazar, Executive Vice President, Connecticut Children's Medical Center • Dr Sujan Shresta, Associate Professor, La Jolla Institute for Immunology • Dr Lauren Wood, CMO, PDS Biotechnology • Dr Bruce Y. Lee, Professor of Health Policy and Management, City University of New York (CUNY), Exec Director of PHICOR, CEO of Symsilico, & Senior Contributor, Forbes • Dr Heidi Zhang, Global Head Analytical Development Cell Therapy, Juno Therapeutics, A Celgene Company • Dr Daryl Drummond, Biotechnology Consultant • Dr Wen Bo Wang, SVP, Technical Operations, Fate Therapeutics • Dr Meghna Das Thakur, Biomarker Lead, T-Cell BiSpecifics, Genentech • Dr Jimmy Linn, CSO, Freenome • Dr Pamela D. Garzone, Chief Medical Officer, Calibr, a division of Scripps Research • Dr Stuart Abbot, CSO, Adicet Bio, Inc • Dr Lenny Moise, Director of Vaccine Research, EpiVax Inc • Dr Patrick Daugherty, CSO and Founder, Serimmune • Dr Anders Lilja, SVP Technical Development, HOOKIPA Pharma • Dr Krishna Prasad, Founder, Citranvi • Dr Risat Jannat, Director, Global Vaccines & Biologics Commercialization, Merck & Co. • Dr Daniel R. Henderson, Ph.D., CEO, CSO, Verndari, Inc. *TBC • Christa Pawlowski, Project Operations Director, SapVax LLC • Dr Victor Defilippis, Associate Professor, Oregon Health and Science • Dr Kena Swanson, Director, Viral Vaccines, Pfizer Vaccine Research & Development • Dr Hong Jin, Senior Director, Fellow R&D - Clinical Pharmacology & Safety Sciences, AstraZeneca Pre-Congress Workshops

Monday 2nd December Choose from either Workshop A or B:

WORKSHOP A WORKSHOP B 1:00 Workshop Leader’s opening remarks: Workshop Leader’s opening remarks: Uses and clinical application of immune profiling Advances in adjuvant technology for vaccines: assays for cancer: Vaccine adjuvants have been used successfully for The use of novel assays and computational methods decades to enhance the ability to provoke an to analyze the immune system is a very fast-moving immune response of weak antigens and improve the field and it is challenging to keep up with the pace of overall potency of vaccines. Join this workshop to change. Join our Advances in Immune Profiling explore the latest advances in novel adjuvant Assays workshop on 2nd December for an in depth technology for vaccines, the value of current look at the uses and clinical application of new adjuvants and how to improve them. methods to characterize and profile the human immune system for the accelerated development of Topics: new therapies. • Adjuvant technology and its impact on vaccine development Topics: • Use of receptor agonists in improving • Assessing base-line immune function existing adjuvants or designing new novel • Assessing predictive biomarkers for PD1 / PDL1 adjuvants for different animal species immunotherapies • Precision adjuvants; tailoring immune • How to assess the efficacy and longevity of activation for next generation vaccines cellular therapies • Assessing the tumor microenvironment • Evaluation of Human Vaccines prior • Discovery of genomic predictors and genomic Vaccination: Of Hope and Hype alterations that promote or suppress immune • Can next generation adjuvants break response tolerance to assist in immune oncology? • Discovery and development of novel biomarkers • Deploying adjuvants for special populations Dr Ignacio Wistuba, Professor & Chair, Department • Combination adjuvants – how should they of Translational Molecular Pathology, MD Anderson be designed and what are the risks Cancer Center • Adjuvating live vaccines Dr I-Ming Wang, Director, Translational Oncology, Dr Darrick Carter, Vice President - Adjuvant Pfizer Technology, IDRI Dr Mark Davis, Professor, Microbiology & Dr Duncan Mwangi, Research Director, Zoetis Immunology, Director, Stanford Institute for Dr Ofer Levy, Director, Precision Vaccines Program, Immunity, Transplantation and Infection, Stanford Boston Children’s Hospital & Professor, Harvard University School of Medicine Medical School Dr Vanessa Jonsson, Assistant Research Professor, Ali Harandi, Lab head, Dpt of Microbiology & City of Hope Immunology, University of Gothenburg Dr Bita Sahaf, Senior Research Scientist; Stanford Dr Victor Defilippis, Associate Professor, Oregon Cancer Institute; Technical Director, PICI Cancer Health and Science Correlative Science Unit Dennis Carson, Professor Emeritus, Medicine, UC San Dr Meghna Das Thakur, Biomarker Lead, T-Cell Diego – invited BiSpecifics, Genentech Additional speakers TBC 5:00 Chair’s closing remarks and end of workshop Main Agenda

Day 1 – Tuesday 3rd December

Day 1 Keynote Plenary Sessions 08.20 Chair’s Opening Remarks 08.30 Immunotherapy 2020 and beyond – what are the next frontiers? • In the last 10 years ground breaking advances and progress have been made in the treatment of cancer with immunotherapy-based approaches. • We have seen approvals of cancer vaccines, multiple single agent and combination checkpoint inhibitor agents in a broad range of tumor types, tissue-agnostic immunotherapy and cellular and gene therapies. • These agents are improving survival and providing cures in some cancer patients. • Several new immunotherapy advancements, opportunities and challenges are on the horizon. Dr Theresa LaVallee, Vice President, Translational Medicine, Parker Institute for Cancer Immunotherapy 08:50 Advances in single cell sequencing and combination of multiple omics data for developing a better understanding of response to immunotherapy and vaccines Dr Richard Scheuermann, Director, La Jolla Campus, J. Craig Venter Institute Dr Lacey Kitch, Director, Informatics, Parker Institute for Cancer Immunotherapy 09.45 The use of vaccines and antibodies in biodefense strategies to combat emerging threats Jeffrey Froude, Major, Stm, Vaccines/Therapeutics Division, Defense Threat Reduction Agency Chia-Wei Tsai, Branch Chief, Antiviral and Antitoxin programs, BARDA Dr. Sina Bavari, Science Director, US Army Medical Research Institute of Infectious Diseases, USAMRIID William Dowling, Microbiologist Science and Technology Manager, Defense Threat Reduction Agency – invited 10.30 Morning Networking Break Meet the Investor Speed Networking: Meet, exchange interests and swap business cards with investors in the biotechnology sector. A great opportunity to maximize your time at the event and meet up to 10 investors in 15mins. Confirmed investors include; Michael Murray, Analyst, Biotechnology Value Fund Mary Jo Potter, Founder and CEO, Healthcare Angels Rajeev Dadoo, Partner, SR One Dr Wouter Meuleman, Director, Venture Investments, Ilumina Ventures Dr Stephen Nagler, Executive Director, MedPro Investors Seth Bannon, Founding Partner, Fifty Years Dr Jennifer Cochran, Chief Scientist, Lagunita Biosciences Additional Investors TBC Immune Profiling Cancer Immunotherapy New Technology Vaccine Development 11.30 Chair’s Opening Chair’s Opening Chair’s Opening Chair’s Opening Remarks Remarks: Remarks Remarks Dr Robert Hollingsworth, Dr Lesley Stolz, EVP & Erin Duffy, PHD Vice President & CSO Chief Business Officer, Chief of Research & Cancer Vaccines, Pfizer Annexon Biosciences Development, CARB-X – invited 11.40 Immuno-Oncology Cancer Vaccines Emerging Technologies Tackling Antimicrobial Resistance Development and Should each patient’s Innovating vaccine How are validation of immune system inform development in space pharmaceutical biomarkers for their immunotherapy? Rachel Clemens, companies contributing Main Agenda

diagnosis and Dr Tom Davis, CMO, Commercial Innovation to the fight against prediction of response Genocea Manager, International antibiotic resistance resistance to Space Station US with the use of vaccines treatment National Laboratory Dr Jan Poolman, Head Dr Ignacio Wistuba, Bacterial Vaccine Professor & Chair, Discovery and Early Department of Development, Janssen Translational Dr Leonard Friedland, Molecular Pathology, Vice President, MD Anderson Cancer Scientific Affairs and Center Public Health Vaccines, 12.10 Intralesional IL12 An integrated machine- RosettaAntibodyDesign North America, GSK enhances anti-PD-1 learning approach to - a platform for Julia Spencer, Associate immune response in improve the prediction computational Vice President, Global treatment-refractory of clinically relevant antibody design Vaccine Public Policy, solid tumors neoantigens Dr Roland Dunbrack, Partnerships, Merck Dr David Canton, Dr Trevor Clancy, Chief Professor, Molecular Timothy Cooke, CEO and Board member, Director, R&D and Scientific Officer, NEC Therapeutics Program, OncoImmunity AS Novadigm Therapeutics Clinical Science, Fox Chase Cancer Dr James Wassil, Vice OncoSec Center President and GH&V BU Head, Vaccines, Pfizer

12.40 Determinants of Artificial Intelligence to Introducing a new Update on the clinical response to the rescue: towards bioparticle platform; development and use CAR-T therapy personalized, design, polyvalence, of a single-dose live oral Dr Francesca Milletti, neoantigen-targeted production and cholera vaccine Associate Director immunotherapeutics immunomodulatory Dr Sean Bennett, Senior Translational Dr Raphael Rousseau, potential Director, Clinical Medicine, Kite, a EVP, Head of Product Development and Louis-Philippe Vézina, Gilead Company Development, CMO, Medical Affairs, PhD, CEO, Angany Inc. Gritstone Oncology Emergent BioSolutions 12:55 Development of EcoCRM®, a new GMP CRM197 carrier protein Dr Andrew Lees, Scientific Director, Fina Biosolutions LLC 1.10 Networking lunch and poster session Innovation & Start up Zone – meet emerging biotechs and discover their innovative platforms and novel technologies in the vaccine & immunotherapy space. Taking place in the exhibition area. Start-up companies include; Meissa Vaccines, Inflammatix, BioGraph 55, Avalia Immunotherapies, StoneStable Inc., InterVen Biosciences 2.10 Understanding the A paradigm shift: Cancer Targeting highly Development of a prognostic and therapy with peptide- conserved influenza bioconjugate vaccine predictive value of based B-cell epitopes virus epitopes with self- against E. coli hyaluronan in the TME and peptide assembled peptides Dr Jan Poolman, Head Invited: Dr Jean-Marie immunotherapeutics Dr Chris Clegg, Bacterial Vaccine Bruey, Executive targeting multiple solid President, Founder & Discovery and Early Director Translational tumor types Development, Janssen CSO, TRIA Bioscience Main Agenda

2:25 Medicine - Clinical Dr Pravin Kaumaya, High yield, high purity Development, Professor, Director, Div. cell separation and Halozyme Vaccine Res & concentration with an Therapeutics Peptide/Protein automated Engineering laboratory, microfluidic-based The Ohio State system University College of Kyle Smith, PhD Medicine Director, Research and Development, Micromedicine 2.40 Decoding cell-free Pfizer’s vaccine Vaccine development Prophylactic and biomarker patterns to immunotherapy in Chikungunya, a therapeutic vaccine optimize the next combination regimen severe disease with approach targeting C. generation of for cancer debilitating long-term difficile infection and precision Dr Robert Hollingsworth, effects and global relapse immunotherapies Vice President & CSO outbreak potential Kevin Killeen, Chief Dr Jimmy Linn, CSO Cancer Vaccines, Pfizer Scientific Officer, Alexander Kort, Senior Freenome Matrivax Vice President Corporate Development, Themis Bioscience GmbH Themis 3.10 Infectious Diseases Oncolytic Viruses Peptide-Based Toxoid Based Overview of Immune Panel: Novel approaches checkpoint receptor Multivalent Vaccine for Epitope Database for the delivery of inhibitors as adjuvants Methicillin-Resistant Dr Biol. Sci. Alex Sette oncolytic viruses and and therapeutics in Staphylococcus Aureus Center Head, Division genes infectious diseases Javad M. Aman, Head, and Professor, Dr Evanthia Galanis, Dr Timothy W Phares, President and CSO, Integrated Center for Infectious Chair Molecular Head of Immunology, Disease, La Jolla Medicine, Professor of Biotherapeutics Explorations in Global Institute for Oncology, Mayo Clinic Health (ExGloH), Leidos Immunology Dr Karen Aboody, 3.25 Professor, Department Engineering vaccine of Developmental & antigens to recruit CD4 Stem Cell Biology and T cell memory for Division of enhanced antibody Neurosurgery, City of responses Hope; Founder & CSO, Lenny Moise, Director Thera Biologics of Vaccine Research, Additional speaker TBC* EpiVax Inc 3.40 Susceptible or Supercharging Identification of novel Immune? A CMV T cell immunotherapy with mycobacterial factors assay accurately novel vector involved in virulence predicts patient status technology harnessing and evasion of host Dr Steven Kleiboeker, the exceptional immune responses in Vice President, immunogenicity of tuberculosis Research & arenaviruses Dr Sangeeta Tiwari, Development, Viracor Dr Anders Lilja, SVP Associate (faculty), Eurofins BioPharma Technical Albert Einstein College Services of Medicine Main Agenda

Development, HOOKIPA Pharma

3.55 Immune monitoring A novel chemistry assays for preclinical platform for coupling and clinical immunogenic peptides development to TLR2-agonist adjuvants to generate fully-synthetic, self- adjuvanting cancer vaccines Christa Pawlowski, Project Operations Director, SapVax LLC 4.10 Afternoon Networking Break 4.40 Induction of innate Immulytic; achieving A novel hybrid virus- Controlling Highly immunity against personalized systemic like-particle technology Infectious Diseases bacterial infection neoantigen vaccination to accelerate the Oral Norovirus Tablet Dr Beckie Ingram, directly in the patient conversion of antigenic Vaccine Senior Lecturer & Dr Praveen epitopes into efficient Sean Tucker, Chief Principal Investigator, Bommareddy, immunogens Scientific Officer & Vice Queens University Translational Research deliverable as vaccines President Research, Belfast Lead, Replimmune David Whitacre, Senior Vaxart Vice President, VLP Biotech 5.10 Developing and Advantages of HSV- Unique Vaccinating against the utilizing positional based oncolytic virus immunotherapy poverty-related scanning therapies for the approach, based on an neglected diseases combinatorial libraries treatment of solid oncolytic virus non- Dr Peter Hotez, for T-lymphocyte tumors covalently combined President of the Sabin antigen discovery Dr Andreas with tumor-specific Vaccine Institute & Dr Clemencia Pinilla, Niethammer, Senior peptides, for a highly Dean of National Associate Member, Vice President, Head of immunogenic and School of Tropical Torrey Pines Institute Clinical Development rapidly adaptable Medicine, Baylor for Molecular Studies Immunotherapy for tumor vaccination College of Medicine Solid Tumors, Sorrento platform. Therapeutics Sari Pesonen, Vice President Scientific And Clinical Development, Co-Founder, Valo Therapeutics 5.40 Human in vitro Armed and dangerous Developing multi- Understanding the modeling to inform against cancer: TGF-beta target single-vector immunology of syphilis precision vaccines for vaccines and delivery using modern Main Agenda

vulnerable trap and personalized devices for Venezuelan technology to develop populations oncolytic adenoviruses Equine Encephalitis a vaccine against this Dr Ofer Levy, Director, Dr Tony Reid, CSO, Virus (VEEV) resurgent pathogen Precision Vaccines EpicentRx Mike Stebbins, MCDC Dr Juan Salazar, Program, Boston Executive Director, Executive Vice Children’s Hospital & Medical CBRN Defense President, Connecticut Professor, Harvard Consortium (MCDC) Children's Medical Medical School Center 6.10 Chair’s Closing Remarks and End of Day 1 Networking Drinks Reception

Main Agenda

Day 2 – Wednesday 4th December Clinical Development Engaging T-Cells, Cancer Immunotherapy Vaccine Development Antibodies, and Bioprocessing, Combinations Manufacture & Delivery 08.30 Chairs Opening Remarks Chairs Opening Chair’s Opening Chair’s Opening Dr Grace Chen, Deputy Remarks: Remarks Remarks Chief of The Clinical Dr. Steven Townson, Dr Kena Swanson, Trials Program in the Senior Principal Director, Viral Vaccines, VRC, NIH Scientist, Early Oncology Pfizer Vaccine Research Development, Merck & Development Research Laboratories 08.40 Vaccines early Combinations & Delivery Vaccines Against development Engaging T-Cells Respiratory Diseases Pre-clinical toxicology Recurrent Stage 4 Opportunities and Mucosal delivery of considerations for Cancer: A patient’s challenges for universal flu vaccine vaccine development journey and hope for integrating delivery antigens in animal Dr Nabil Al Humadi, the future technologies into cancer models Pharmacologist and Chester Kitchen, Cancer immunotherapy Xiaoping Zhu, Interim Toxicologist, Food and Patient Advocate Dr Michael J. Mitchell, Associate Dean & Drug Administration Ph.D., Skirkanich Department Chair, Assistant Professor of University of Maryland Innovation, Department of Bioengineering, University of Pennsylvania 09.10 Novel correlates of Combinations and Development of novel Developing a single protection against checkpoint inhibitors; antibody-directed vaccine to protect pandemic influenza what’s working? nanotherapeutics (ADN) against all influenza Dr Aubree Gordon, Dr Maria Karasarides, for infectious diseases strains using ground- Associate Professor of Executive Director, and cancer breaking mathematical Epidemiology, University Immuno-Oncology, Dr Daryl Drummond, models and research of Michigan Regeneron Head of Research, Dr Brian Price, COO, Pharmaceuticals Merrimack Blue Water Vaccines, Inc Pharmaceuticals

09.40 The Potential Impact of Versamune; a novel T- Bioprocessing and Broader protective a Norovirus Vaccine in cell activating manufacture influenza vaccine the U.S. immunotherapy Engineering bispecific Naik Rumi Armaghan, Dr Bruce Y. Lee, platform IgM antibodies as cancer Ph.D., Director and Head Professor of Health Dr Lauren Wood, CMO, therapeutics of Design Sciences in Policy and Management, PDS Biotechnology Dr Bruce Keyt, CSO, IGM FluNXT, Sanofi Pasteur’s City University of New Biosciences “Biotech-lite” York (CUNY), Exec Director of PHICOR, CEO of Symsilico, & Senior Contributor, Forbes Main Agenda

10.10 Executing animal rule Overcoming the Design & manufacture Protection against studies in high immunosuppressive of next generation Respiratory Syncytial containment TME by targeting biotherapeutics with a Virus (RSV) by maternal Dr Jason Comer, Myeloid-Derived scalable biochemical immunization Assistant Professor, Suppressor Cells protein synthesis Kathrin Jansen, Senior Department of Raymond Tesi, platform Vice President of Microbiology and CEO/CMO, INmune Bio Dr Maureen Bruhns, Vaccine Research and Immunology, University Senior Director of Early Development of Texas Medical Branch Analytical Development, Pfizer at Galveston Sutro Bio 10.25 Using serology to support vaccine development Patrick Daugherty, CSO and Founder, Serimmune

10.40 Morning Networking Break 11.30 Interactive Roundtables Interactive discussions with like-minded peers tackling the similar challenges in vaccine, antibody and immunotherapy development (Roundtables run twice each for 45mins, select two options) Strategies to improve Advances in the Single cell sequencing Managing toxicity in patient stratification by intratumoral to understand response combination interrogating the tumor administration of to vaccines and immunotherapy microenvironment cancer agents immunotherapy Invited: Dr Pamela Dr Kirsteen Maclean, Dr Adil Daud, Clinical Munster, Professor, PhD., Associate, Professor of Medicine, Department of Medicine; Scientific Director, Director, Melanoma Director, Early Phase Biomarker & Clinical Research, UCSF Clinical Trials Unit, Co- Translational Strategy Helen Diller Family leader of the Center for Definiens Comprehensive Cancer BRCA Research, UCSF Center Helen Diller Family Comprehensive Cancer Center Challenges in defining Strategies of combining Generation of Changing landscape of TMB and its relevance in small molecule TKIs antibodies to novel real-world evidence and its different tumor types and immunotherapies targets impact on clinical research Invited: Dr Vasileios Dr Gary Starling, – uncovering lab & clinical Askoxylakis. Director, Associate Vice adverse events Clinical Program Leader President, Protein at Novartis Institutes Science, Merck for BioMedical Research (NIBR) Main Agenda

Managing process Novel approaches to The road map to NIH’s Meet the investor: your improvements for accelerate the grant application questions answered. vaccines discovery, development process. How to find Dr Stephen Nagler, Dr Justin Moran, Senior and translation of new out more about the Executive Director, Director Bioprocess passive and active current programs MedPro Investors Development, Pfizer immunization for available Additional investors TBC targeted diseases Susan Old, Acting Deputy Director, NIAID, NIH Best practices for Early engagement of Flavivirus vaccine – Influenza vaccination and outsourcing sites: Advantages for induced immune the diversity paradox manufacture of biologics sponsors and CROs responses using mouse Dr Craig Thomson, CSO, through CMOs William Smith, MD, models Blue Water Vaccines, Inc Dr Vadim CEO, Alliance for Dr Sujan Shresta, Klyushnichenko, VP Multispecialty Associate Professor, La Pharmaceutical Research (AMR) Jolla Institute for Development & Quality, Immunology Calibr – a division of Scripps Research 1.10 Networking Lunch and Poster session

Innovation & Start up Zone – meet emerging biotechs and discover their innovative platforms and novel technologies in the vaccine & immunotherapy space. Taking place in the exhibition area. Start-up companies include; Meissa Vaccines, Inflammatix, BioGraph 55, Avalia Immunotherapies, StoneStable Inc., InterVen Biosciences

2.30 Infectious Disease Early CD40 agonists to A plug-and-play A novel live attenuated Development & Trials enhance antigen approach to creating RSV vaccine Exploring different Non- presentation, resulting differentiated antibody Dr Martin Moore, Co- Human Primate models in improved quality and Founder & CEO, Meissa drug candidates used for Tuberculosis magnitude of T-cell Vaccines Patricia Darrah, Staff responses Scientist, NIH – invited Dr Ovid Trifan, CMO & SVP Clinical Development, Apexigen 3.00 Immunologic causes and A novel WT1-targeting Custom-designed linker RSV F and G Sequence bacterial sources of multivalent heteroclitic technology to improve Evolution Over the reactivation TB and epitope antibody drug 2016-2019 RSV Seasons relapse after treatment immunotherapeutic: conjugates in the USA and its Dr Philana Ling Lin, clinical update Invited: Dr Michael Implications in Vaccine Associate Professor, Dr Angelos Stergiou, Kaufman, SVP, CMC, and Anti-RSV Drug Department of CEO, SELLAS Life Mersana Therapeutics Development Pediatrics, University of Sciences Dr Hong Jin, Senior Pittsburgh – invited Director, Fellow R&D - Clinical Pharmacology & Safety Sciences, AstraZeneca Main Agenda

3.30 Title TBC Antibody-based Designing cutting edge Emerging and Re- Max Ciarlet, Head, Early therapies vaccine and Emerging diseases and Exploratory Clinical Leveraging bispecific biotechnology Development of a Development Cluster, molecules for the manufacturing Chikungunya VLP Novartis Vaccines and combination platforms *topic title vaccine Diagnostics – invited immunotherapy of TBC Sarah, Royalty Tredo, cancer Charles Heffernan, Senior Director, Dr Jon Wigginton, SVP, Member, BioPhorum Emergent Biosolutions Clinical Development & Operations Group; Chief Medical Officer, Director, CRB MacroGenics 4.00 Afternoon Networking Break 4.30 Immuno-Oncology Early Updates in the Rapid manufacture and A natural killer T (NKT) Development & Trials development of next scale-up of off-the-shelf cell adjuvanting vaccine Designing Immuno- generation BiTE cell therapies platform induces liver- Oncology trials to immunotherapies Dr Wen Bo Wang, SVP, resident memory CD8+ maximizing clinical Invited: Dr Gregory Technical Operations, T cells that protect outcomes and chances Friberg, Vice President Fate Therapeutics against malaria of success and Therapeutic Area Dr William Heath, Dr Jun Tang, Senior Head (Global Professor, University of Manager, CRI Venture Development), Amgen Melbourne, Scientific Fund and Clinical Advisor, Avalia Accelerator, Cancer Immunotherapies Research Institute Limited 5.00 Clinical perspectives and Developing Antibody- Improving autologous A phase II trial of a live conclusions in oncology Drug-Conjugates to CAR-T access and attenuated virus Dr Julie Brahmer, unique embryonic affordability tetravalent dengue Professor of Oncology, cancer stem cell targets Dr Heidi Zhang, Global vaccine in healthy US John Hopkins – invited Dr Mike Schopperle, Head Analytical adults CEO & Founder, Development Cell Stephen Thomas, CureMeta Therapy, Juno Deputy Commander of Therapeutics, A Celgene Operations, Walter Reed Company (BMS) Army Institute of Research – invited 5.30 Trial Designs for Vaccine Clinical development of Manufacturing Development of single Therapies and next generation operations and dose vaccines for Personalized Medicine Antibody Drug efficiencies for emerging and re- in Oncology Conjugates personalized mRNA emerging infectious Mary Redman, Associate Dr Nancy Whiting, vaccines diseases, preclinical data Member, Clinical Senior Vice President, Dr Matthew Barrows, for Ebola, Marburg, Research Division, Fred Development, Seattle Director RNA Lassa Fever and Zika as Hutchinson Cancer Genetics Operations, examples Research Center Personalized Cancer Dr Farshad Guirakhoo, Vaccine Manufacturing, CSO, GeoVax Moderna Therapeutics *TBC

6.00 Chair’s closing remarks and end of day 2 Drinks reception Main Agenda

Day 3 – Thursday 5th December

Clinical Development Engineered Cancer Vaccine delivery, Infectious Disease Therapies bioprocessing & Antibodies manufacture 09.00 Chair’s Opening Chair’s Opening Chair’s Opening Chair’s Opening Remarks Remarks Remarks Remarks 09.10 Clinical Trial Analysis Unleashing the Vaccine Bioprocessing & Passive immunity and Design potential of gene Manufacture strategies in infectious Clinical Trials in an therapy using the non- Development and diseases International Setting viral UltraCAR-T licensure of an Ebola Vu Truong, Chief Moderator: Dr Peter platform for vaccine Executive Officer and Hotez, President of the hematological and solid Dr Risat Jannat, Director, Chief Scientific Officer, Sabin Vaccine Institute tumors Global Vaccines & Aridis Pharmaceuticals & Dean of National Dr Helen Sabzevari, Biologics Larry Zeitlin, President, School of Tropical President, Precigen Commercialization, Mapp Medicine, Baylor Merck & Co. Biopharmaceutical, Inc College of Medicine Dr Joseph Kim, Chief 09.40 Dr Bruno Anspach, Development of next Advances in Executive Officer, Director of Clinical generation allogenic development of Inovio Pharmaceuticals Operations Latin CAR-T therapies conjugate and multi- America - vaccines, component vaccines GSK Dr Krishna Prasad, Willem Hanekom, Founder, Citranvi Deputy Director, TB Vaccines, Bill & Melinda Gates Foundation Jo Anne Welsch, Scientific Director, Group B Streptococcal Vaccine Project, PATH 9:55 Experimental human challenge models used in respiratory track diseases and malaria 10.10 Dr Jerald Sadoff, Senior Non-genetically A unique platform for Anti-Ebola mAbs Advisor Vaccine modified, multi-antigen research scale to mid- currently being used in Development, Janssen T cell therapies with scale, host-independent the Ebola outbreak in Infectious Diseases and improved effectiveness biological manufacturing DRC Vaccines over conventional CAR- Alexander Koglin, PhD, Nancy Sullivan, Chief T/ TCR approaches Co-founder, Chief and Biodefense Reserved, Marker Science and Technology Research Section, Therapeutics Officer, NTxBIO Vaccine Research Center National Institutes of Health Main Agenda

10.25 Site’s perspective on A new vaccine strategy AI and its application in frequent issues around to boost T-cell therapy vaccine manufacture vaccine trials Invited: Dr Darrell Irvine, William Smith, Chief Professor of Materials Executive Officer, Science & Engineering Alliance for and Biological Multispecialty Engineering, Massachusetts Institute Research of Technology; Co- LLC founder, Strand Therapeutics 10.40 Morning Networking Break 11.10 Using computational Targeting natural Recent innovation in Monoclonal antibody and informatics tools neoantigens through vaccine manufacture development against or toxicology and adoptive cellular Invited: Dr Tony infectious diseases in safety assessment for therapies D’Amore, Vice President, pediatric populations antibody projects Dr Stephen Product Kalpit Vora, Director, Schoenberger, Center Research and infectious disease and Head; Professor Division Development, Sanofi Vaccine Basic of Developmental Pasteur Research, Merck Immunology, LaJolla Institute for Immunology

11.40 Clinical Trials in Late Identification of novel Challenges in vaccine Antibody-based Stages T-cell receptor targets manufacture in LMICs therapy to combat Drug development and specificity profiling Dr Laskshmi Khandke, Staphylococcus aureus challenges within of TCRs tested in the Senior Program Advisor, infections immune-oncology and clinic to develop safe & Center for Vaccine Hasan Jafri, Senior analytical approaches effective TCR therapies Innovation & Access, Director, Clinical Dr Hanspeter Gerber, Research and to address them PATH CSO, 3T Bioscience Development, Pralay Mukhopadhyay, Infectious Disease and Head of Late stage IO, Vaccines, MedImmune Oncology Biometrics, AstraZeneca 12.10 Planning and executing Immuno-STAT – A novel Vaccine Delivery Development of pre-launch strategies platform for the VaxiPatch™ a new, antibiotic drug to lead vaccines selective modulation of unique and proprietary conjugates successfully to the antigen-specific T-cells delivery technology that Wouter Hazenbos, market Dr John Ross, VP of eliminates needle Scientist, Genentech Julie Post, Director, Protein Therapeutics, phobia, the cold chain Late Stage Pipeline Cue Biopharma and sharps waste? Dr Daniel R. Henderson, Vaccines (North Ph.D., CEO, CSO America), Pfizer – Verndari, Inc. *TBC invited Expanding vaccine effectiveness with needle-free delivery Reserved Main Agenda

12.40 Real World Data to Gamma delta T-cells: A Development of a Rapid antibody support oncology universal, off-the-shelf versatile, single-injection development for clinical trials immune cell therapy to vaccine formulation Biodefense use Dr William Capra, treat cancer and other platform that can Global Head of Real- diseases enhance immune World Data, Oncology, Dr Stuart Abbot, CSO, response Genentech/ Roche – Adicet Bio, Inc Dr Eric Appel, Assistant invited Professor of Material Science and Engineering, Stanford University 1.10 Networking lunch and poster session Innovation & Start up Zone – meet emerging biotechs and discover their innovative platforms and novel technologies in the vaccine & immunotherapy space. Taking place in the exhibition area. Start-up companies include; Meissa Vaccines, Inflammatix, BioGraph 55, Avalia Immunotherapies, StoneStable Inc., InterVen Biosciences Day 3 Plenary Keynote Sessions 2.10 Chair’s Opening Remarks 2.20 Microbiome and epigenetic imprinting of immune responses to vaccination in humans Professor Bali Pulendran, Professor in the Department of Pathology and Laboratory Medicine, Stanford University School of Medicine 2.50 What will be the impact of moving towards earlier lines of therapy in cancer? • Novel diagnostics and early detection initiatives • How will this change how we think about resistance? • What happens when we reach maximal amount of t-cell responses? • If immune capability decreases with subsequent lines of therapy is it a good idea to delay? Will investigational therapies preclude a patient from getting chemo? • Modifying the immune system to respond to immunotherapy • How does immunotherapy interact with radiation? • How will this affect drug candidate pipelines? Dr Ezra Cohen, Professor of Medicine, UCSD Moores Cancer Center, Co-director, San Diego Center for Precision Immunotherapy Dr Martina Sersch, CMO, Mustang Bio Dr Pamela D. Garzone, Chief Medical Officer. Calibr, a division of Scripps Research 3.50 Creating a public-private partnership to advance global health Invited: Dr Andrin Oswald, Director, Life Science Industry Partnerships, Bill & Melinda Gates Foundation 4.20 Chair’s closing remarks and end of congress

Agenda Overview

The 3rd World Vaccine & Immunotherapy Congress will take place December 3 – 5 in San Francisco, 2019

Please contact [email protected] & [email protected] for 2019 speaking opportunities.

Organised by

Floorplan